The largest community of pharma leaders

Immunomic Therapeutics Announces Promotion of Teri Heiland, Ph.D. to Chief Scientific Officer

ROCKVILLE, Md.–(BUSINESS WIRE)–#allergies–Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the promotion of Teri Heiland, Ph.D. to Chief Scientific Officer. In her new role, Dr. Heiland will oversee all of research and development and will play an integral role in business development and the management of ITI’s existing and future partnerships. Dr. Heiland is a co-founder of ITI and has amassed over two decades of executive leadership….

Recent Articles